EUVIMEDEUVIMED entdecken
Crossref

Multi‐Architecture Nanovaccines Against Pseudorabies Virus and Particle Size‐Governed Immune Activation Mechanisms

Meng Zhang, Chunxin Wang, Cailing Meng, Xinglong Xu, Jinghui Zhan, Ying Li, Qing Wang, Junqian Pan, Haixin Cui, Xiang Zhao iD

Advanced Healthcare Materials · 2026-02 · 15 (8)

DOI: 10.1002/adhm.202503382 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 03.12.2025. Verfasst von Meng Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Environment and Sustainable Development in Agriculture, Chinese Academy of Agricultural Sciences, Beijing, P. R. China. Hauptthemen laut MEDLINE: Herpesvirus 1, Suid, Pseudorabies, Nanoparticles, Pseudorabies Vaccines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key R&D Program of China, Basic Scientific Research Foundation of National Non-Profit Scientific Institute of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pseudorabies virus (PRV), characterized by latent infection, lifelong viral shedding, and high mortality rates, has inflicted substantial economic losses on the swine industry. While vaccination remains the most cost‐effective control strategy, emerging virulent variants with enhanced immune evasion capabilities have compromised conventional vaccines, manifesting as short‐lived protection, suboptimal efficacy, and risks of latency reactivation. To overcome rapid antigen clearance and undefined immunomodulatory mechanisms in traditional emulsion vaccines, we engineered three nanoemulsions with distinct architectures and sizes: an oil‐in‐water nanovaccine (O/W nanovaccine, 163.1 ± 3.84 nm), a water‐in‐oil‐in‐water nanovaccine (W/O/W nanovaccine, 32 ± 4.04 nm), and a Pickering emulsion nanovaccine (326.07 ± 9.19 nm). The immunogenicity and biocompatibility of nanoemulsion formulations are systematically evaluated through in vitro cellular models, followed by comprehensive in vivo investigations in murine/porcine models to elucidate immune mechanisms, protective efficacy, and challenge resistance. All formulations demonstrated immunostimulatory potential with distinct functional advantages. O/W nanovaccine exhibited superior antigen‐presenting cell uptake efficiency and sustained cytokine induction. W/O/W nanovaccine showed maximal dendritic cell activation and high‐titer neutralizing antibodies. Pickering emulsion nanovaccine enhanced specific antibody titers. In addition, mechanistic studies revealed that nanoscale lymphatic targeting of O/W nanovaccine and W/O/W nanovaccine leveraged immune cell size preferences for polyfunctional cytokine release. Multi‐layered design of W/O/W nanovaccine enabled compartmentalized antigen delivery, induced CD8+ T cell response, and synergistically enhanced cross‐presentation to elicit coordinated humoral and cellular immunity. Particulate‐stabilized interface of Pickering emulsion nanovaccine enhanced humoral immunity via DC‐mediated IFN‐γ hyper‐secretion and CD4+ T cell differentiation. Furthermore, all nanovaccines demonstrated higher protective efficacy compared to commercial vaccines in animal challenge models infected with PRV, O/W nanovaccine achieved 100% survival in mice while exhibiting the lowest viral shedding in pigs. This study establishes a transformative prevention paradigm against PRV through nanovaccine engineering, providing critical insights for developing next‐generation veterinary vaccine platforms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Herpesvirus 1, SuidPseudorabiesNanoparticlesPseudorabies VaccinesViral VaccinesAnimalsMiceSwineParticle SizeEmulsionsAntibodies, ViralFemaleNanovaccines

Stichwörter der Autor:innen

PRVimmune mechanismslymphatic targetingnanoemulsion vaccine

Substanzen

EmulsionsAntibodies, ViralPseudorabies VaccinesViral VaccinesNanovaccines

Autor:innen und Institutionen

  • Institute of Environment and Sustainable Development in Agriculture, Chinese Academy of Agricultural Sciences, Beijing, P. R. China.
  • Northwest A&F University, Shaanxi, P. R. China.

ORCID-Profile: Xiang Zhao

Förderung

  • National Natural Science Foundation of China
  • National Key R&D Program of China
  • Basic Scientific Research Foundation of National Non-Profit Scientific Institute of China
  • Key Technologies R&D Program of Guangdong Province
  • National Key Research and Development Program of China

Zitieren

APA

Zhang, M., Wang, C., Meng, C., Xu, X., Zhan, J., Li, Y., Wang, Q., Pan, J., Cui, H., & Zhao, X. (2026). Multi‐Architecture Nanovaccines Against Pseudorabies Virus and Particle Size‐Governed Immune Activation Mechanisms. Advanced Healthcare Materials, 15(8). https://doi.org/10.1002/adhm.202503382

Vancouver

Zhang M, Wang C, Meng C, Xu X, Zhan J, Li Y, et al. Multi‐Architecture Nanovaccines Against Pseudorabies Virus and Particle Size‐Governed Immune Activation Mechanisms. Advanced Healthcare Materials. 2026;15(8). doi:10.1002/adhm.202503382

BibTeX
@article{Zhang2026,
  author = {Zhang, Meng and Wang, Chunxin and Meng, Cailing and Xu, Xinglong and Zhan, Jinghui and Li, Ying and Wang, Qing and Pan, Junqian and Cui, Haixin and Zhao, Xiang},
  title = {Multi‐Architecture Nanovaccines Against Pseudorabies Virus and Particle Size‐Governed Immune Activation Mechanisms},
  journal = {Advanced Healthcare Materials},
  year = {2026},
  volume = {15},
  number = {8},
  doi = {10.1002/adhm.202503382}
}
Kostenlos starten →